NR3C2 and chronic kidney disease: Our study did not incorporate details on medications that have been shown to slow the progression of CKD—such as sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and nonsteroidal mineralocorticoid receptor antagonists—which have demonstrated benefits in preventing CVEs in the nontransplant population.